Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

NCT03587207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningitis, Meningococcal

Interventions

BIOLOGICAL: MenABCWY vaccine
BIOLOGICAL: rMenB+OMV NZ (Bexsero) vaccine
BIOLOGICAL: MenACWY (Menveo) vaccine

Sponsor

GlaxoSmithKline